N

Nicholas J. Short

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-2983-2738

1.1k papers and 17.5k citations.

PubIndex Score99Top 1% · mid-careerHow it's scored

🌱#3 Emerging Leader in Theological Perspectives and Practices 🌱#7 Emerging Leader in Chronic Myeloid Leukemia Treatments

1.1kPublications

17.5kTotal Citations

#3in Theological Perspectives and Practices

First publication: 1981First senior author: 2016

Top publicationsby citations

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Hagop M. Kantarjian, Curtis A. Lachowiez et al.|Journal of Clinical Oncology|2021

Cited by 333

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur et al.|The Lancet Haematology|2020

Cited by 330

Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax

Kunhwa Kim, Marina Konopleva, Abhishek Maiti et al.|Cancer|2021

Cited by 156

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid Malignancies

Curtis A. Lachowiez, Courtney D. DiNardo, Sanam Loghavi et al.|Blood Cancer Discovery|2023

Cited by 122

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors

Ahmad S. Alotaibi, Naval Daver, Musa Yılmaz et al.|Blood Cancer Discovery|2020

Cited by 97

Indexing the rest of 1,094 publications…